Professor Chris Triggle



School /
Work Unit

Medical Sciences

Contact Details

No Phone


City campus


Science, Engineering & Health

"Professor Chris Triggle"

Summary of Responsibilities

Professor Chris Triggle is the Director of the Biotechnology VRII with responsibilities to facilitate and promote the growth of biotechnology at RMIT, as well to strengthen national and international collaborations.

Professor Triggle is also an Innovation Professor and a Professor of Pharmacology with an appointment in the School of Medical Sciences.He is currently the Head of the Microvascular Research Group.This group focuses on microvascular physiology and pharmacology with ongoing projects that are aimed at identifying the mechanisms that control contraction and relaxation in microvascular smooth muscle, particularly in response to mechanical and chemical stimuli.

Research projects are closely linked to understanding disease states notably, and diabetic angiopathies and hypertension.

Professor Triggle’s research group has established collaborations with the University of New South Wales in Sydney and the University of Calgary in Canada.


B.Sc. (Hons) University of East Anglia (UK), 1967

PhD (Pharmacology) University of Alberta (Canada), 1972

Teaching responsibilities

Professor Triggle teaches at both the undergraduate and graduate levels in areas related to pharmacology and drug development, as well as supervising postgraduate research students and postdoctoral fellows.

Research interests

  • Vascular smooth muscle–endothelial cell interactions with an emphasis on the contributions of nitric oxide vs. “endothelium-derived hyperpolarizing factor” (EDHF) to the regulation of vascular tone.
  • Type 2 diabetes and the role of endothelial dysfunction as both an early indicator of the cardiovascular morbidity associated with diabetes as well as a potential target for therapeutic intervention.
  • The detection and physiological function of nitric oxide stores (S-nitrosothiols) in vascular tissue.

Industry / profession / community involvement


  • Pharmacological Society of Canada 1975 - present
    President (1989 - 1991)
    Vice President (1987 - 1989)
    Councillor (1979 - 1981 incl.)
  • Canadian Hypertension Society 1979 - present
    Member of the Board (1992 - 1997)
  • International Society for Hypertension 1988 - present
  • American Society for Pharmacology and Experimental Therapeutics 1988 - present
  • Western Pharmacology Society 1990 - present
    Councillor (1993 - 1996)
    President-elect (1996 - 1997)
  • Australasian Society of Clinical & 1999 - present
    Experimental Pharmacologists & Toxicologists

National / International Committees

  • Chair, Canadian Institutes of Health Research, Grants Review Committee, Cardiovascular Committee “C”, December 2001-June 2004.
  • Chair, Heart and Stroke Foundation of Canada, Committee IVA, December 2001-2004
  • Member of the Michael Smith Foundation for Health Research Review Committee, September 2003-presentEditorship of Journals
  • Associate Editor, Canadian Journal of Physiology and Pharmacology, 1980-1986; 2004-present
  • Editorial Board, Pharmaceutical News, 1993-2004
  • Editorial Board, Drug Development Research, 1993-present
  • Editorial Board, Clinical and Experimental Pharmacology and Physiology, 1996-present
  • Editorial Board, British Journal of Pharmacology, 1999-2003

Research publications

(140 to date with 32, excluding book chapters, 1999-2004):

Ko, L., Maitland, A., Fedak, P.W., Dumont, A.S., Badiwala, M., Lovren, F., Triggle, C.R., Anderson, T.J., & Verma, S. Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins. Ann. Thorac. Surg. 73: 1185-1188, 2002.

McGuire, J.J. Hollenberg, M.D., Amrade-Gordon, P., & Triggle, C.R. Multiple mechanisms of vascular smooth muscle relaxation by the activation of Protease-Activated Receptor 2 in mouse mesenteric arterioles. Br. J. Pharmacol. 135: 155-169, 2002.

Wanstall, J.C. Jeffery, T.K., Gambino, A., Lovren, F., & Triggle, Christopher R. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br. J. Pharmacol. 136: 463-472, 2002

Pannirselvam, M., Verma, S., Anderson, T.J. & Triggle, C.R. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br. J. Pharmacol. 136: 255-263, 2002.

McGuire, J., Dai, J., Andrade-Gordon, P., Triggle, C.R., & Hollenberg, M.D. Proteinase-activated receptor-2 (PAR2): Vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J. Exp. Pharmacolol. & Therap. 303: 985-992, 2002.

Andrews, K., Triggle, C.R., Ellis, A. NO and the vasculature: Where does it come from and what does it do? Heart Failure Reviews 7: 423-445, 2002.

Ko, L., Maitland, A., Fedak, P.W., Dumont, A.S., Badiwala, M., Lovren, F., Triggle, C.R., Anderson, T.J., & Verma, S. Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins. Ann. Thorac. Surg. 73: 1185-1188, 2002.

Pannirselvam, M., Anderson, T.J., & Triggle, C.R. Endothelial cell dysfunction in Type I and II Diabetes –The cellular basis for dysfunction. Drug Development Research 58: 28-41, 2003.

Ding, H. & Triggle, C.R. The Contribution of EDHF and the role of potassium channels in the regulation of vascular tone. Drug Development Research 58: 81-89, 2003.

Andrews, K.l., McGuire, J.J & Triggle, C.R. A photosensitive vascular smooth muscle store of nitric oxide in mouse aorta: No dependence on expression of endothelial nitric oxide synthase. Br. J. Pharmacol. 138:932-940, 2003.

McGuire, J.J & Triggle, C.R. Searching for the physiological role and therapeutic potential of vascular Proteinase-Activated Receptor-2 (PAR2). Drug Development Research 60: 14-19, 2003.

Pannirselvam, M., Simon, V., Jiang, Y., Wiehler, W.B., Verma, S., Anderson, T.J., & Triggle, C.R. Chronic treatment with sepiapterin prevents endothelial dysfunction and oxidative stress in mesenteric arteries from diabetic (db/db) mice. British J. Pharmacology, 140: 701-706, 2003.

Triggle, C.R., Pannirselvam, M., Anderson, T.J.& Ellis, A Lack of inhibitory effect of catalase on endothelium-dependent relaxations in mouse and rat small mesenteric arteries. British Journal of Pharmacology. 140: 1193-2000, 2003.

Ellis, A., & Triggle, C.R.Involvement of endothelium-derived reactive oxygen species in the regulation of vascular tone. (A Survey Review). Canadian Journal of Physiology and Pharmacology. 81: 1013-1028, 2003.

Triggle, C.R. Hollenberg, M., Anderson, T.J., Ding, H., Jiang, Y., Ceroni, L., Wiehler, W.B., Ng, E.S.M., Ellis, A., Andrews, K., McGuire, J.J. & Pannirselvam, M. The endothelium in health and disease – A target for therapeutic intervention (An invited Review). Journal of Smooth Muscle Research. 39: 249-267 2003.

McGuire, J.J., Saifeddine, M., Triggle, C.R., Sun, K., & Hollenberg, M.D.

2-furoyl-LIGRLO-amide: A potent and selective Proteinase-Activated Receptor 2 (PAR-2) agonist. J. Pharmacology & Exp. Therapeutics In Press 2004.

Academic management / administration responsibilities

  • Director of Biotechnology VRIIProjects and consultancies

Projects and consultancies

  • Former Research Director/Consultant with Ciba and Novartis, Canada, 1992-2000.
  • Former President of Neurospheres, Canada.Awards


  • Memorial University of Newfoundland Research Professorship.Award for Outstanding Research, 1989 - 1994 (awarded in 1989)